Antipsychotics are the cornerstone of schizophrenia treatment, with the crowded atypical and typical antipsychotic drug classes resulting in a complex treatment algorithm. Given the genericization…
MARKET OUTLOOK Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide spectrum of clinical symptoms ranging from…
Introduction: NASH is characterized by a buildup of excess lipid (steatosis) in the liver, resulting in inflammation and eventually liver damage, leading to fibrosis and subsequently cirrhosis and…
MARKET OUTLOOK Treatment for PsA typically begins with a cDMARD, but often progresses to a tsDMARD or bDMARD within two years. TNFi are the mainstay of treatment for recently treated…
Rheumatoid arthritis (RA) treatment typically begins with one or more conventional DMARDs, followed by a first-line biologic, usually a TNF-α inhibitor. Patients refractory to one or more TNF-α…
Ulcerative colitis (UC) patients, particularly those with more mild disease activity, will be prescribed a conventional therapy (e.g., 5-ASAs) as first-line treatment; there are multiple generics…
The primary goal of ulcerative colitis (UC) treatment is to induce and maintain remission with few to no clinical symptoms remaining. Conventional therapies (e.g., 5-ASAs, corticosteroids) are…
Painful diabetic neuropathy (PDN) in the United States is defined as having had numbness, loss of feeling, or painful sensations in the feet within the last three months. PDN is managed by multiple…
In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as IL-12/23 inhibitor Stelara (Janssen), have been leading the U.S. psoriasis biologics market. However, the…
Painful diabetic neuropathy (PDN) in the United States is defined as having had numbness, loss of feeling, or painful sensations in the feet within the last three months. PDN is managed by multiple…
MARKET OUTLOOK Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins, but DRG anticipates that the number of treatment options will grow over the next ten years. Intensive…
Market Outlook Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only other oral targeted therapy, besides Celgene’s PDE-4 inhibitor, Otezla,…
MARKET OUTLOOK Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins, but DRG anticipates that the number of treatment options will grow over the next ten years. Intensive…
Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data…